Drugs / Nanoxel®M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02982395 | Jan 2017 → Aug 2018 | urinary bladder carcinoma | Samyang Biopharmaceuticals Corporation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NanoxelM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02982395 ↗ |
| Route | Other | “Intravesical” NCT02982395 ↗ |